Sphingosine-1-phosphate receptor agonists in the treatment of demyelinating disorders

摘要

Abstract Disclosed are pharmaceutical combinations comprising at least one S1P receptor agonist, as well as a method for treating demyelinating diseases, e.g. multiple sclerosis or disorders associated therewith or Guillain-Barrd syndrome, comprising co-administration, e.g. concomitantly or In sequence, of a therapeutically effective amount of a) an S1 P receptor agonist, and b) at least one co-agent shown to have clinical activity against at least one symptom of a demyelinating disease.